AI-generated summary
The authors report a systematic review of 16 human and animal studies, including four randomized controlled trials, on photobiomodulation therapy for mood disorders published from 2009 to 2021. They describe commonly used infrared settings of 800 to 830 nm and rate PBMT as strongly recommended for moderate major depressive disorder and recommended for anxiety, while stating that bipolar disorder needs further study.
- Studies included
- 16
- Who or what was studied
- People with mood disorders, including major depressive disorder, anxiety disorder and bipolar disorder, along with animal studies
- Wavelengths
- 800, 830 nm
- Limits stated in the abstract
- Only four of the included studies were randomized controlled trials, and just two of those were rated high quality.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 800 to 830 nm
- Energy density (fluence)
- 120 J/ cm2
- Power density (irradiance)
- 250 mW/cm2
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Systematic review, GRADE, Wavelength, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.